These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27792891)

  • 1. Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO.
    Schneider EK; Reyes-Ortega F; Wilson JW; Kotsimbos T; Keating D; Li J; Velkov T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1038():57-62. PubMed ID: 27792891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients.
    Schneider EK; Reyes-Ortega F; Li J; Velkov T
    J Vis Exp; 2017 Oct; (128):. PubMed ID: 29155707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rapid LC-MS/MS method for the simultaneous quantification of ivacaftor, lumacaftor, elexacaftor, tezacaftor, hexyl-methyl ivacaftor and ivacaftor carboxylate in human plasma.
    Zheng Y; Rouillon S; Khemakhem M; Balakirouchenane D; Lui G; Abdalla S; Sanoufi MR; Sauvaitre L; Thebault L; Hirt D; Treluyer JM; Gana I; Benaboud S; Froelicher-Bournaud L
    J Pharm Biomed Anal; 2024 Sep; 248():116322. PubMed ID: 38964167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
    Schneider EK; Azad MA; Han ML; Tony Zhou Q; Wang J; Huang JX; Cooper MA; Doi Y; Baker MA; Bergen PJ; Muller MT; Li J; Velkov T
    ACS Infect Dis; 2016 Jul; 2(7):478-88. PubMed ID: 27626100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability.
    Vonk SEM; van der Meer-Vos M; Bos LDJ; Neerincx AH; Majoor CJ; Maitland-van der Zee AH; Mathôt RAA; Kemper EM;
    Ther Drug Monit; 2021 Aug; 43(4):555-563. PubMed ID: 33165217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum.
    Habler K; Kalla AS; Rychlik M; Bruegel M; Teupser D; Nährig S; Vogeser M; Paal M
    Clin Chem Lab Med; 2022 Jan; 60(1):82-91. PubMed ID: 34668357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor.
    Schneider EK
    Drug Metab Lett; 2018; 12(1):71-74. PubMed ID: 29595119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor-ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis-an observational study.
    Arooj P; Morrissy DV; McCarthy Y; Vagg T; McCarthy M; Fleming C; Daly M; Eustace JA; Murphy DM; Plant BJ
    BMJ Open Respir Res; 2023 May; 10(1):. PubMed ID: 37130650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation.
    Pohl K; Nichols DP; Taylor-Cousar JL; Saavedra MT; Strand MJ; Nick JA; Bratcher PE
    PLoS One; 2018; 13(12):e0209026. PubMed ID: 30540818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN; Hanna C; Giovane R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
    Schneider EK; Reyes-Ortega F; Li J; Velkov T
    Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method.
    Reyes-Ortega F; Qiu F; Schneider-Futschik EK
    ACS Pharmacol Transl Sci; 2020 Oct; 3(5):987-996. PubMed ID: 33073196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia.
    Liu Z; Anderson JD; Rose NR; Baker EH; Dowell AE; Ryan KJ; Acosta EP; Guimbellot JS
    Pulm Pharmacol Ther; 2024 Sep; 86():102314. PubMed ID: 38964603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function.
    Burgel PR; Durieu I; Chiron R; Mely L; Prevotat A; Murris-Espin M; Porzio M; Abely M; Reix P; Marguet C; Macey J; Sermet-Gaudelus I; Corvol H; Bui S; Biouhee T; Hubert D; Munck A; Lemonnier L; Dehillotte C; Silva JD; Paillasseur JL; Martin C;
    J Cyst Fibros; 2021 Mar; 20(2):220-227. PubMed ID: 32591294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.
    Barnaby R; Koeppen K; Nymon A; Hampton TH; Berwin B; Ashare A; Stanton BA
    Am J Physiol Lung Cell Mol Physiol; 2018 Mar; 314(3):L432-L438. PubMed ID: 29146575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis.
    Kopp BT; McCulloch S; Shrestha CL; Zhang S; Sarzynski L; Woodley FW; Hayes D
    Pediatr Pulmonol; 2018 May; 53(5):583-591. PubMed ID: 29461009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Glucose Breath Test in Cystic Fibrosis Patients Treated With 1 Month of Lumacaftor/Ivacaftor.
    Gabel ME; Wang H; Gelfond D; Roach C; Rowe SM; Clancy JP; Sagel SD; Borowitz D;
    J Pediatr Gastroenterol Nutr; 2022 Jul; 75(1):42-47. PubMed ID: 35442228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orkambi® and amplifier co-therapy improves function from a rare
    Molinski SV; Ahmadi S; Ip W; Ouyang H; Villella A; Miller JP; Lee PS; Kulleperuma K; Du K; Di Paola M; Eckford PD; Laselva O; Huan LJ; Wellhauser L; Li E; Ray PN; Pomès R; Moraes TJ; Gonska T; Ratjen F; Bear CE
    EMBO Mol Med; 2017 Sep; 9(9):1224-1243. PubMed ID: 28667089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development.
    Harbeson SL; Morgan AJ; Liu JF; Aslanian AM; Nguyen S; Bridson GW; Brummel CL; Wu L; Tung RD; Pilja L; Braman V; Uttamsingh V
    J Pharmacol Exp Ther; 2017 Aug; 362(2):359-367. PubMed ID: 28611092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.